Development of a Vaccine Targeting the TadE Protein to Solve the Acne Problem

Kırkız İ., Çavaş L.

7th Eurasia Biochemical Approaches & Technologies (EBAT), Antalya, Türkiye, 6 - 09 Kasım 2025, ss.1-2, (Özet Bildiri)

  • Yayın Türü: Bildiri / Özet Bildiri
  • Basıldığı Şehir: Antalya
  • Basıldığı Ülke: Türkiye
  • Sayfa Sayıları: ss.1-2
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Research on vaccines has accelerated thanks to immunoinformatic. The immunoinformatic tools effectively investigates the candidate vaccines and choose the best ones for the treatment. Cutibacterium acnes TadE proteins are promising candidates for the vaccine treatment. In this research, multi epitope-based vaccine design against Cutibacterium acnes was proposed. The antigenic potential of 28 TadE proteins were evaluated via VaxiJen 2.0.1 Five proteins with the A0AA44U4S4, F9NTD2, H9ZMR3, A0A2B7J2H3 and A0AA44U2F7 accession numbers were chosen for further investigation since they have the highest scores. IEDB was used to predict MHCI and MHCII binding epitopes and maximum scores were found as “ASLSVEVLMW” for HLA-B*57:01 and “SRTVHATGSAPVDTY” for HLA-DRB1*07:01, respectively.2 B-cell epitopes were identified using BepiPred2.0, ABCpred and SVMTriP.3-4 AlgPred and AllerTOP v2.1 tools were used to evaluate the allergenicity of protein sequences and most of the proteins were found to be non-allergenic.5-6 In conclusion, since topical and systemic antibiotics are being used to treat acne vulgaris, organisms start to develop antibiotic resistance. Therefore, more advanced treatments for the acne vulgaris are required and peptide-based vaccines may be a pioneer for those studies.